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Aims Some patients show such an important clinical improvement and reverse remodelling after cardiac resynchronization
therapy (CRT) that anatomy and function approach normal. These patients have been called ‘super-responders’. The
aim of our study was to identify predictors of becoming a super-responder after CRT.
Methods
and results
Eighty-seven consecutive patients who underwent CRT were prospectively studied. Before CRT and 6 months after,
clinical and echocardiographic evaluation was performed. Patients with a decrease in New York Heart Association
functional class 1, a two-fold or more increase of left ventricular ejection fraction (LVEF) or a final LVEF .45%,
and a decrease in LV end-systolic volume .15% were classified as super-responders. There were 12% super-respon-
ders. At baseline, there were no significant differences between super-responders and the other patients, except for
the fact that super-responders had significantly smaller mitral regurgitation and LV end-diastolic diameter (LVEDD)
and a shorter duration of heart failure symptoms. Mitral regurgitation jet area, LVEDD, and duration of heart failure
symptoms were correlated with this super-response. Moreover, an evolution of symptoms for ,12 months was an
independent predictor of super-response to CRT.
Conclusion Patients in earlier phases of the cardiomyopathy, with a less altered ventricular geometry, seem to have a greater
probability of becoming super-responders.
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Introduction
Cardiac resynchronization therapy (CRT) is recommended for
heart failure patients who remain in symptomatic New York
Heart Association (NYHA) class III or IV despite optimal medical
treatment, with normal sinus rhythm, low left ventricular ejection
fraction (LVEF) (,35%), left ventricular (LV) dilation, and QRS
duration .120 ms.1,2
Cardiac resynchronization therapy improves symptoms and
exercise capacity and also decreases heart failure hospitalizations
and all-cause mortality when added to optimal pharmacotherapy
in patients with advanced heart failure.3 However, up to 30% of
patients receiving CRT do not have a positive clinical or reverse
remodelling response.4 In contrast, some patients who underwent
CRT show such an important clinical improvement and left ventri-
cular reverse remodelling that anatomy and function approach
normal.1 These patients have been called ‘super-responders’ to
CRT, and it is expected that they will have the best outcome
after CRT.
A decrease in LV end-systolic volume (LVESV) .15% is clinically
relevant, because this value has a high sensitivity and specificity for
the prediction of long-term all-cause and cardiovascular mortal-
ities. Furthermore, this cut-off value of LV reverse remodelling
also predicts heart failure events and composite endpoints of car-
diovascular hospitalization or mortality. In fact, LV remodelling
seems to be the strongest predictor of long-term survival after
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CRT. Therefore, volumetric assessment by echocardiography is
not only a surrogate marker of a favourable cardiac response to
CRT, but also an objective measure that predicts long-term clinical
outcomes.5
Previously, the search for optimal and easily detectable predic-
tors of response to CRT has attracted a lot of attention; neverthe-
less, there are very few data concerning super-responders to CRT.
Recently, Castellant et al.6 have proposed to consider patients as
super-responders if they concurrently fulfilled two criteria: func-
tional recovery and LVEF 50%. However, in our opinion, this
definition of super-responder is not satisfactory because it does
not consider LV reverse remodelling (the best predictor of long-
term survival after CRT), and it should be more specific regarding
LVEF. We may have patients with a very low baseline LVEF, an
excellent LV reverse remodelling, and up to four-fold improve-
ment of LVEF after CRT (for example, from 10 to 40%) who
would not be considered super-responders according to the defi-
nition of Castellant et al. Should these patients not be considered
super-responders?
At present, the mechanisms by which some patients have this
excellent response to CRT and others have no benefit remain to
be determined.
The aim of our study was to identify predictors of being a super-
responder to CRT. We also propose a new definition of super-
responders to CRT.
Methods
Inclusion criteria and study protocol
This is a prospective study that involved a single centre. The study
population included 87 consecutive patients with dilated cardiomyopa-
thy (DCM) who underwent CRT since November 2005 to October
2007. The majority of patients were in NYHA functional class III or
IV, despite optimal medical treatment. All patients had echocardio-
graphic LVEF ,35% and QRS duration .120 ms (with left bundle
branch block configuration), or QRS duration 120 ms but mechan-
ical dyssynchrony documented by echocardiography [intraventricular
dyssynchrony .40 ms and interventricular dyssynchrony (IVD)
.40 ms]. The protocol was approved by our institutional Research
Ethics Committee. All patients gave informed consent, and the
study complied with the Declaration of Helsinki. Before CRT and
6 months after, demographic, echocardiographic, and clinical par-
ameters (including NYHA class) were assessed. At the 6 months
follow-up, patients were classified as ‘super-responders’ to CRT if
they showed a reduction of one or more NYHA functional classes, a
two-fold or more increase of the LVEF from baseline or to an absolute
value .45%, and a decrease in the LVESV .15%. Non-responders
were defined as patients with an improvement in LVESV 15% or
who had been re-hospitalized for the management of chronic heart
failure or died during follow-up.
Pacemaker implantation
The LV pacing lead was inserted by a transvenous approach through
the coronary sinus, with an over-the-wire system, into either the
lateral or postero-lateral cardiac vein whenever possible. The right
atrium and right ventricle were stimulated by positioning standard
bipolar catheters in the right atrial appendage and right ventricular
apex, respectively. The epicardial approach was used in the case of
unsuccessful conventional implantation of the LV lead. When a
conventional indication for an internal defibrillator existed, a combined
device was implanted. Optimization of the AV delay was performed
using Doppler echocardiography, interrogating transmitral flow with
the sample volume at the tip of the mitral valve leaflets in order to
obtain the best flow velocity profile.
Echocardiography
Standard echocardiography, including tissue Doppler imaging (TDI),
was performed using an ATL IDH 5500 Philips System (Vingmed—
General Electric, Horten, Norway) before and 6 months after biventri-
cular pacing device implantation. Left ventricular dimensions were
measured from M-mode echocardiography in the parasternal long-axis
view, and LV stroke volume was calculated with quantitative Doppler
by multiplying the LV outflow tract by the time–velocity integral of
blood flow at this level.7 The LV end-diastolic volume (LVEDV),
LVESV, and LVEF were assessed by the biplane Simpson’s equation
in apical four-chamber and two-chamber views.8 The sphericity
index was calculated as the ratio of LVEDV and the volume of a
sphere, with a diameter equal to the LV end-diastolic long axis (LA)
(SI ¼ 6LVEDV/pLA3).9 Another measurement of systolic function
evaluated was mitral regurgitation dP/dt. Left ventricular diastolic func-
tion was assessed with the evaluation of LV inflow diastolic velocities
with pulse-wave Doppler (E and A velocities). We assessed the ratio
of peak flow velocity in early diastole and peak flow velocity in late dia-
stole during atrial contraction (E/A), the deceleration time of E-wave,
isovolumic relaxation time as the interval between the end of aortic
flow and the beginning of mitral inflow, and the mitral regurgitation
jet area (JA)1 as a mitral regurgitation severity parameter. The IVD
was calculated as the time difference between the aortic and pulmon-
ary pre-ejection time intervals (from QRS to the onset of flow), where
aortic and pulmonary ejection flows were recorded in the five-
chamber apical and parasternal views, respectively.
To assess dyssynchrony, the time delay between the onset of QRS
complex on the surface electrocardiogram and the onset of the systo-
lic velocity wave on the TDI recording were assessed in four basal LV
segments (septal, lateral, anterior, and inferior). Intraventricular dys-
synchrony (TS-Intra-VD) was calculated as the difference between
the longest and the shortest time delays in the four basal segments.
Additionally, IVD (TS-Intra-VD) was calculated as the difference
between time to peak systolic velocity at the right ventricular free
wall and the most delayed LV segment.
Statistical analysis
Statistical analyses were performed using SPSS software version 15.
Results are expressed as mean+ standard deviation or median and
25th to 75th percentiles for continuous variables and as counts and
percentages for categorical variables. Data were compared with
paired or unpaired Student’s t test when appropriate. Non-parametric
Mann–Whitney test was used for comparison of continuous variables
between super-responders and the other patients when variables were
not normally distributed. Discrete variables were compared with the
x2 test or Fisher’s exact test, whichever appropriate.
Efficacy of CRT was examined by comparing baseline vs. follow-up
parameters using Student’s paired t-test for comparisons of quantitat-
ive variables and by the McNemar test for comparisons of qualitative
variables.
A multivariate, logistic regression analysis was used to identify base-
line variables to be predictive of a super-response to CRT.
P, 0.05 was considered statistically significant.
N. Anto´nio et al.344











In the study population, 55 patients were males (63%) and 32
females (37%). The mean age was 62+11 years. Nineteen
patients were in NYHA class IV (22%), 59 in class III (68%), and
9 in class II (10%). The cause of heart failure was ischaemic in 31
(36%) patients and non-ischaemic in 56 patients. The mean dur-
ation of QRS was 145+ 32 ms, with 14 patients (17%) presenting
a QRS duration ,120 ms. Thirteen patients (15%) presented with
chronic atrial fibrillation (AF). Severe dilation of the LV was
observed in most patients [mean LV end-diastolic diameter
(LVEDD) of 75+10 mm, mean LV end-systolic diameter
(LVESD) of 63+ 10 mm, mean LVEDV of 279+ 116 mL, and
mean LVESV of 214+100 mL], associated with a mean LV ejec-
tion fraction of 24+7%. Tissue Doppler imaging demonstrated
substantial LV dyssynchrony in this population (83+50 ms).
A combined device was implanted in 74% of patients (90% of the
super-responders group vs. 71% of the other group, P ¼ 0.274).
There were no significant differences regarding the pacemaker
implantation procedure, namely in the lead position, between
super-responders and the other patients.
Incidence of super-responders
Among the 87 patients with DCM, 10 (12%) demonstrated a
reduction of one or more NYHA functional class, an increase in
the LVEF to two-fold or more the baseline LVEF or to an absolute
value .45%, and a decrease in the LVESV .15%, 6 months after
CRT. These patients, who had no re-hospitalizations for the man-
agement of congestive heart failure, were considered super-
responders to CRT. In 34 patients (38.4%), the LVESV did not
reduce or had a reduction ,15% after CRT (non-responders).
Differences of baseline characteristics
between super-responders
and the other patients
Regarding baseline characteristics, there were no statistically signifi-
cant differences between super-responders and the other patients,
except for the fact that super-responders had significantly smaller
mitral regurgitation, smaller LV diastolic diameters (LVDDs), and
shorter duration of heart failure symptoms (Table 1). Super-
responders also tended to present more intraventricular dyssyn-
chrony and IVD, higher QRS duration before CRT, and less fre-
quently ischaemic cardiomyopathy than the other patients.
However, there were no significant statistically differences
between the two groups regarding these parameters.
One of the super-responders was in AF, another one had a QRS
,120 ms, and two of them were in NYHA class II before CRT.
Effects of cardiac resynchronization
therapy: 6 months of follow-up
After CRT, we observed a significant improvement of NYHA func-
tional class, LVEF, LV diameters, mitral regurgitation JA, intraventri-
cular dyssynchrony, and IVD in both groups. Left ventricular
end-systolic volume showed a significant decrease in both
groups; however, LVEDV reduced significantly only in the super-
responder group (Table 2). Regarding the magnitude of response,
LV volumes, LVEF, and LVESD showed a significantly greater
improvement in super-responders than in the other patients
(Figure 1). The variation of NYHA functional class, intraventricular
dyssynchrony and IVD, and mitral regurgitation JA was not signifi-
cantly different between the two groups.
There were no re-admissions for heart failure 6 months after
CRT in the super-responder group and a re-admission rate of
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Table 1 Comparison of baseline characteristics of super-responders and the other patients
Super-responders (n5 10) Other patients (n 5 77) P-value
Male gender (%) 60 64 0.54
ICM (%) 50 34 0.32
Age (years) 60+8 62+11 0.41
NYHA class 3.0+0.7 3.1+0.6 0.66
Duration of symptoms (months) 15.1+17.8 33.9+35.7 0.01
QRS duration (ms) 153.5+30.8 143.5+31.6 0.30
JA (cm2) 5.4+6.7 8.1+5.4 0.04
LVEDD (mm) 69.3+6.4 75.3+10.0 0.04
LVESD (mm) 57.3+7.5 63.6+10.2 0.06
LVEDV (mL) 244.4+72.8 267.9+110.4 0.60
LVESV (mL) 192.8+72.3 204.8+94.0 0.79
Sphericity index 0.62+0.11 0.66+0.16 0.48
LVEF (%) 22.5+8.6 24.4+6.5 0.43
LV dP/dt (mmHg/s) 515.8+247.4 476.3+160.5 0.89
Intraventricular dyssynchrony (ms) 113.0+96.7 78.8+40.2 0.37
Interventricular dyssynchrony (ms) 57.0+35.6 49.1+23.4 0.35
ICM, ischaemic cardiomyopathy; JA, mitral regurgitation jet area; LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter; LVEDV, left
ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; LVEF, left ventricular ejection fraction.
Identification of super-responders to CRT 345









10.9% in the remaining patients. No cardiac deaths occurred during
the 6-month follow-up. In eight patients, there were implantable
cardioverter defibrillator (ICD) shocks, which were appropriate
in two cases. In super-responder group, only one patient had an
ICD shock and it was inappropriate. Finally, one patient (who
was not a super-responder to CRT) needed cardiac transplan-
tation during the follow-up period.
Predictors of super-response to cardiac
resynchronization therapy
In the bivariate analysis, variables correlated with super-response
to CRT were mitral regurgitation JA (r ¼ 20.212, P ¼ 0.048),
LVEDD (r ¼ 20.213, P ¼ 0.048), and the duration of heart
failure symptoms (r ¼ 20.308, P ¼ 0.011). Moreover, LVEDD
was inversely correlated with the improvement of LVEF after
CRT (Figure 2).
In the multivariate logistic regression analysis, mitral regurgita-
tion JA and LVEDD were not independent predictors of super-
response to CRT. In fact, the only independent predictor of this
successful result was duration of symptoms for ,12 months
(OR 6.03; IC: 1.17–31.02) (Figure 3).
Patients in New York Heart Association
class II at baseline
We compared the effects of CRT in patients in NYHA class II with
those in NYHA class III or IV. Before CRT, there were no signifi-
cant clinical, electrocardiographic, or echocardiographic differ-
ences between the two groups, except for IVD that was higher
in class II patients (117.2+ 91.7 vs. 78.7+42.4 ms; P, 0.05).
After CRT, NYHA class II patients showed a significant improve-
ment of LVEF, LVESV, LVEDV, and mitral regurgitation JA. Patients
in class III or IV at baseline also showed significant improvement of
LVEF, LVESV, and mitral regurgitation JA, but not LVEDV (Table 3).
Regarding the magnitude of improvement, patients in NYHA
class II presented a similar increase in LVEF and the same reduction
of the mitral regurgitation as patients in NYHA class III or IV. More-
over, class II patients showed a significantly greater reduction of LV
volumes (reduction of LVESV: 58.9+62.7 vs. 21.0+43.6 mL; P ¼
0.021 and reduction of LVEDV: 51.2+56.0 vs. 9.3+46.5 mL; P ¼
0.014).
There were no re-hospitalizations for heart failure management
during follow-up in patients in NYHA class II at baseline. However,
patients in NYHA class III or IV at baseline presented
re-hospitalization rate of 7.7%.
These results suggest that the benefit of CRT in class NYHA II
patients is the same or even greater than that demonstrated for
patients in higher functional classes.
Discussion
Despite the encouraging results from CRT in recent trials, patient
responses to CRT may vary significantly. Some patients can do




In our population, 12% of the patients treated with CRT for refrac-
tory heart failure can be identified as super-responders. This pro-
portion is similar to previously reported results, ranging from 13 to
16%.6,10
This ideal response was more likely to occur in patients with less
altered ventricular geometry. In fact, patients with lower LV diam-
eters and mild-to-moderate mitral regurgitation seem to have a
greater probability of having a complete reverse remodelling and
becoming super-responders after CRT than those with severely
altered ventricular geometry. However, neither LVEDD nor mitral
regurgitation JA were independent predictors of super-response
to CRT. Likewise, despite the trend of super-responders to have
more dilated idiopathic cardiomyopathy, to have a wider QRS,
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Table 2 Six-month follow-up results in




































*P, 0.05 follow-up vs. baseline value.
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and to be more desynchronized at baseline, these parameters were
not significantly different between groups and were not indepen-
dent predictors of such exceptional response to CRT.
In our work, an evolution of heart failure symptoms for ,12
months was an independent predictor of super-response to
CRT, suggesting that resynchronization could be more efficient
in the earlier phases of the disease.
Super-responders in off-label indications
for cardiac resynchronization therapy
The present study demonstrated for the first time to our knowl-
edge that this potential normalization of LV systolic function and
anatomy can be achieved even in patients with AF. This is consist-
ent with previous observations that have described a comparable
CRT effect between sinus rhythm and AF groups in terms of
improvement of functional capacity and LV function.11 Likewise,
narrow QRS duration or NYHA class II does not seem to
prevent complete reverse remodelling. Recent studies have pro-
vided increasing evidence that CRT induced similar or even
better improvement in LV function, reverse remodelling, and sur-
vival in patients with NYHA class II compared with those in
NYHA class III or IV.12,13 These findings are in favour of a beneficial
effect of CRT on disease progression in patients with mild heart
Figure 1 Comparison of the variation in left ventricular ejection fraction and left ventricular end-systolic volume between super-responders
and the other patients.
Figure 2 Correlation between baseline left ventricular diastolic
diameter and variation in left ventricular ejection fraction after
cardiac resynchronization therapy.
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failure and may justify the possibility of having super-responders
with lower baseline NYHA class. Our work further extends
these findings by showing that patients with a history of ,12
months of symptoms benefit the most from CRT.
To the best of our knowledge, the possibility of having super-
responders even if they lack the classical indications to CRT has
never been previously described.
Clinical implications
Our work demonstrated that super-responders to CRT are not
rare in the real world. Additionally, these results suggest that
patients with a less altered LV geometry have a higher probability
of being super-responders. This may have important therapeutic
implications. If confirmed by large, long-term, multi-centre
studies, these results may lead to CRT in earlier phases of the
cardiomyopathy when the probability of complete reverse remo-
delling is higher. Finally, this is the first report of super-responders
in off-label indications to CRT.
Study limitations
This is a single-centre, observational cohort study. The most
important limitations of this study are the small number of patients
included and the relatively short period of follow-up.
Further studies with larger number of patients are warranted to
confirm these results.
Conflict of interest: none declared.
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